Based on a subgroup analysis by PD-L1 expression from KEYNOTE-811, Merck is working with the US FDA to update the current indication for KEYTRUDA in HER2-positive gastric or GEJ adenocarcinoma
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Economic analysis of cost of Vall d’Hebron University Hospital Stroke Unit shows direct-to-angio stroke pathway can save more than USD 3,000 per patient
Patent Term Extension is designed to restore some of the patent life lost during the regulatory review process for new drugs.
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development
The application is in line with Innocan's strategy to expand the scope of its combined magnesium and cannabis topical solution
UTD2 is the world's first oral epothilone microtubule inhibitor
Application being reviewed under the FDA Project Orbis framework, which enables concurrent reviews among US, Australia, Canada, Switzerland, Singapore and United Kingdom health authorities
Coverage of CGHS cities has expanded from 25 cities in 2014 to 80 in 2023
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
Subscribe To Our Newsletter & Stay Updated
